Artiva Biotherapeutics Shares Rise on FDA RMAT Designation for AlloNK

By EC Assets · Published 8 June 2026

Artiva Biotherapeutics stock experienced a surge following the United States Food and Drug Administration (FDA) granting Regenerative Medicine Advanced Therapy (RMAT) designation. This designation was for AlloNK in refractory rheumatoid arthritis (RA). The company plans to proceed with a Phase 3 trial for AlloNK. The RMAT status follows data presented at EULAR 2026. The data showed a 71% ACR50 at six months in refractory RA patients receiving AlloNK plus rituximab. Artiva Biotherapeutics highlighted this AlloNK data at EULAR 2026, alongside the FDA RMAT designation in refractory rheumatoid arthritis. A webcast was scheduled for the same day as these announcements. The RMAT designation is for AlloNK in refractory RA. This article is intended for informational purposes only. It does not constitute investment advice.